Literature DB >> 7720439

Severe Clostridium difficile colitis.

M S Rubin1, L E Bodenstein, K C Kent.   

Abstract

PURPOSE: Reports of fatality related to Clostridium difficile colitis and a sharp increase in prevalence of this infection prompted a study of patients who develop a more aggressive form of this disease.
METHODS: Over 38 months, 710 patients at our institution developed C. difficile colitis. Twenty-one (3 percent) of these patients either required intensive care unit admission or died as a result of their infection. A retrospective, case-controlled study was undertaken to compare these patients, who were considered to have severe C. difficile colitis, with the remaining patients with milder disease.
RESULTS: Factors that predisposed to the development of severe C. difficile colitis included intercurrent malignancy, chronic obstructive pulmonary disease, immunosuppressive and antiperistaltic medications, renal failure, and administration of clindamycin (P < 0.05 for all). Patients with severe C. difficile colitis were more likely to have abdominal pain, tenderness and distention, peritonitis, hemoconcentration (> 5 points), hypoalbuminemia (< 3 mg/dl), and elevated or suppressed white blood cell count (> 25,000; < 1,500; P < 0.05 for all). These factors were used to create a scoring system that could distinguish between patients with severe C. difficile colitis and those with mild disease. Thirteen patients in the late stages of terminal illness with metastatic malignancy or age > 90 were considered poor or inappropriate surgical candidates. Only the remaining eight patients could have potentially recovered from operation with hope for long-term survival. Of these, seven were treated without colonic resection, and six of the seven survived, whereas one patient underwent colectomy and did not survive.
CONCLUSIONS: Patients with severe C. difficile colitis can be readily identified. Often they have coexisting illness that precludes operation. In this series, only 1 of 21 patients with severe C. difficile might have benefited from an aggressive surgical approach.

Entities:  

Mesh:

Year:  1995        PMID: 7720439     DOI: 10.1007/bf02054220

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  47 in total

Review 1.  Intravenous immunoglobulin for the treatment of Clostridium difficile infection: a review.

Authors:  Marwan S Abougergi; John H Kwon
Journal:  Dig Dis Sci       Date:  2010-10-06       Impact factor: 3.199

2.  Diagnostic approach to Clostridium difficile infection.

Authors:  Chetana Vaishnavi
Journal:  Indian J Gastroenterol       Date:  2010-08-18

3.  Management of severe Clostridium difficile-associated diarrhea.

Authors:  Michael J Krier; George Triadafilopoulos
Journal:  Dig Dis Sci       Date:  2009-02-19       Impact factor: 3.199

Review 4.  Drug-induced diarrhoea.

Authors:  O Chassany; A Michaux; J F Bergmann
Journal:  Drug Saf       Date:  2000-01       Impact factor: 5.606

5.  The impact of Clostridium difficile on a surgical service: a prospective study of 374 patients.

Authors:  K C Kent; M S Rubin; L Wroblewski; P A Hanff; W Silen
Journal:  Ann Surg       Date:  1998-02       Impact factor: 12.969

Review 6.  Clostridium difficile and inflammatory bowel disease: role in pathogenesis and implications in treatment.

Authors:  Orna Nitzan; Mazen Elias; Bibiana Chazan; Raul Raz; Walid Saliba
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

7.  Univariate and multivariate analysis of risk factors for severe Clostridium difficile-associated diarrhoea: importance of co-morbidity and serum C-reactive protein.

Authors:  Christian Hardt; Thomas Berns; Wolfgang Treder; Franz-Ludwig Dumoulin
Journal:  World J Gastroenterol       Date:  2008-07-21       Impact factor: 5.742

8.  Markers of intestinal inflammation, not bacterial burden, correlate with clinical outcomes in Clostridium difficile infection.

Authors:  Rana E El Feghaly; Jennifer L Stauber; Elena Deych; Carlos Gonzalez; Phillip I Tarr; David B Haslam
Journal:  Clin Infect Dis       Date:  2013-03-13       Impact factor: 9.079

Review 9.  Variations in virulence and molecular biology among emerging strains of Clostridium difficile.

Authors:  Jonathan J Hunt; Jimmy D Ballard
Journal:  Microbiol Mol Biol Rev       Date:  2013-12       Impact factor: 11.056

10.  Recombinant single-chain variable fragment antibodies directed against Clostridium difficile toxin B produced by use of an optimized phage display system.

Authors:  Xiao K Deng; Lance A Nesbit; K John Morrow
Journal:  Clin Diagn Lab Immunol       Date:  2003-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.